Drugs / LY4395089
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07592572 | May → Jul 2026 overdue | — | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07483099 | May 2026 → Jun 2027 expected | Crohn disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07483073 | May 2026 → Jun 2027 expected | Crohn disease, ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4395089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483099 ↗ |
| Action | Activate | “a farnesoid X receptor (FXR) agonist (LY4395089)” NCT07483099 ↗ |
| Route | Oral | “Administered orally” NCT07483073 ↗ |